Positive Results and New Technology Give Rise to Antibody Dominance; (TSXV: $IPA.V) (OTC: $IPATF) (TSX: $ZYME.TO) (NASDAQ: $SESN) (TSX: $PMN.TO)
Point Roberts, WA and Delta, BC - March 27, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot looking at the biopharmaceutical market and how monoclonal antibody research is gaining market dominance.
GELifesciences.com, talking about the Antibody boom says; "Many small and start-up companies are developing new ideas as to how antibodies can be used. In many cases, these companies will go on to be acquired by larger companies with the financial capability to progress their ideas further. But with costs to establish manufacturing capability in suitable existing buildings at not much more than $10-15 M, this strategic opportunity lies within reach even for smaller businesses. Despite steep competition and the need for significant investment, the antibody space is a lucrative opportunity with various therapeutic avenues that can be explored."
Looking at some companies in the sector, Immunoprecise Antibodies Ltd. (TSXV: IPA) (OTC: IPATF), a therapeutic antibody discovery company, recently received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute (NCI). Under the subcontract, IPA will discover and produce rabbit monoclonal antibodies using its proprietary B-Cell Select platform.
The rabbit monoclonal antibodies discovered and produced under this subcontract will be used in the key applications of immunohistochemistry and immuno-Multiple Reaction Monitoring (immuno-MRM). The antibodies will be generated for NCI's Antibody Characterization Program.
Immuno-MRM is a leading-edge targeted mass spectrometry technique that relies on antibodies to enrich peptides from complex biological samples that are then quantified by mass spectrometry. Rabbit monoclonal antibodies are highly sought after for this purpose because they exhibit high specificity and bind their target with high affinity. Immuno-MRM is being used to discover novel biomarkers and develop a new generation of clinical diagnostic tests that could lead to improved cancer detection, diagnosis, and treatment.
Zymeworks Inc. (NYSE: ZYME) (TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics reported in January the achievement of a new development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks' 2014 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$8.0 million for Lilly's submission of an IND application for an immuno-oncology bispecific antibody enabled by Zymeworks' proprietary Azymetric™ platform.
Sesen Bio, Inc. (NASDAQ: SESN), a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of cancer recently reported positive preliminary efficacy data for the primary endpoint of its ongoing Phase 3 registration trial, the VISTA Trial, of Vicinium® for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) and deemed BCG-unresponsive. The data reported show clinically meaningful complete response rates in evaluable Carcinoma in situ patients at three, six, nine and twelve months of follow-up in the trial consistent with the data in the completed Phase 1 and Phase 2 clinical trials. Importantly, Vicinium continues to be generally well-tolerated in treated patients.
ProMIS Neurosciences, Inc. (TSX: PMN) (OTC: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases will soon present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease. ProMIS Neurosciences' Chief Scientific Officer, Dr. Neil Cashman will discuss the preclinical data at a podium presentation on March 31 as well as co-moderate the March 30 panel discussion on disease mechanisms in Alzheimer's disease and Parkinson's disease.
ResearchandMarkets, in a biopharma market overview reported, "The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%."
Within the related segments, Monoclonal Antibodies are expected to gain the largest market size.
For investors following medical technology and healthcare stocks, Investor Ideas has created a directory of biotech and medical technology stocks
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI
Follow us on Social Media
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Disclosure: this news article featuring (TSX VENTURE: IPA) (OTC PINK: IPATF) a paid for service on Investorideas.com(third party). Learn more about costs and our services https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.